Form 4: Olema Pharmaceuticals Director, Yi Larson, Acquires 23,000 Stock Options

Yi Larson, a director of Olema Pharmaceuticals, acquired 23,000 stock options on June 14, 2024, at an exercise price of $12.36.

Summary

• On June 14, 2024, Yi Larson, a director of Olema Pharmaceuticals, acquired 23,000 stock options.
• The exercise price for these options is $12.36.
• The options vest in 12 equal monthly installments starting from June 14, 2024, contingent upon continuous service.
• Full vesting occurs on the date of the Issuer's next annual meeting of stockholders if not fully vested before, subject to continuous service.
• The options expire on June 14, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard insider transaction, suggesting confidence from a director. It's a neutral-to-positive indicator.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The vesting schedule is tied to continuous service, incentivizing the director to remain with the company.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded pharmaceutical companies.
• The vesting schedule of 12 months is fairly standard, aligning with typical performance review cycles.
• Comparable companies such as Arvinas and Relay Therapeutics also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially driving long-term value creation.

Key Dates